skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Next-generation drug-eluting stents in coronary artery disease: focus on everolimus-eluting stent (Xience V®)

Review

(2965) Views  (915) Full article downloads

Authors: Imad Sheiban, Gianluca Villata, Mario Bollati, Dario Sillano, Marzia Lotrionte, Giuseppe Biondi-Zoccai

Published Date March 2008 Volume 2008:4(1) Pages 31 - 38
DOI: http://dx.doi.org/10.2147/VHRM.S1838

Imad Sheiban1, Gianluca Villata1, Mario Bollati1, Dario Sillano1, Marzia Lotrionte2, Giuseppe Biondi-Zoccai1

1Interventional Cardiology, Division of Cardiology, University of Turin, Turin, Italy; 2Institute of Cardiology, Catholic University, Rome, Italy

Abstract: Percutaneous coronary revascularization has been a mainstay in the management of coronary artery disease since its introduction in the late 1970s. Bare-metal stents and, more recently, first-generation drug-eluting stents (DES), such as sirolimus-eluting (Cypher®) and paclitaxel-eluting stents (Taxus®), have further improved results of percutaneous coronary intervention (PCI) by improving early results and reducing the risk of restenosis. There is currently debate on the safety of these first-generation DES, given the potential for late stent thrombosis, especially after discontinuation of dual antiplatelet therapy. There are well known caveats on the performance of their respective metallic stent platforms, delivery, and dilation systems, and polymer coatings. Second-generation DES, such as zotarolimus-eluting (Endeavor®) and everolimus-eluting stents (Xience V®), have recently become available in the USA and/or Europe. The Xience V stent holds the promise of superior anti-restenotic efficacy as well as long-term safety. In addition, this stent is based on the Multi-link platform and delivery system. Recently available data already suggest the superiority of the Xience V stent in comparison to the Taxus stent in terms of prevention of restenosis, without significant untoward events. Nonetheless, the number of patients studied and the follow-up duration are still too limited to enable definitive conclusions. Only indirect meta-analyses can be used to date to compare the Xience V with the Cypher. This systematic review tries to provide a concise and critical appraisal of the data in support of the Xience V everolimus-eluting stent.

Keywords: coronary artery disease, everolimus, percutaneous transluminal coronary angioplasty, stent








Readers of this article also read:

Endothelial effects of antihypertensive treatment: focus on irbesartan
Kaposiform hemangioendothelioma with distant lymphangiomatosis without an association to Kasabach-Merritt-Syndrome in a female adult!
Immediate and six months clinical and angiographic results of intracoronary paclitaxel-coated stent implantation – the Meo:DrugStar-1 study
Update on the everolimus-eluting coronary stent system: results and implications from the SPIRIT clinical trial program
Retinal nerve fiber layer evaluation in multiple sclerosis with spectral domain optical coherence tomography
Retinal nerve fiber layer thickness in recovered and persistent amblyopia
Methemoglobinemia due to topical pharyngeal anesthesia during endoscopic procedures
Erratum
Absorbable stent: focus on clinical applications and benefits
The burden of chronic obstructive pulmonary disease among employed adults
  • Join ISVH

    Be part of the World's leading experts in vascular health by joining the International Society of Vascular Health (ISVH)

  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University